兒童及成人用藥品類均呈現增長態勢,葵花葯業(002737.SZ)半年度扣非淨利潤預增50.98%-73.35%
格隆匯7月13日丨葵花葯業(002737.SZ)公佈,預計2023年半年度實現營業總收入29.25億元-31.51億元,同比增長30.05%-40.08%;歸屬於上市公司股東的淨利潤6億元-6.6億元,同比增長49.54%-64.50%;扣除非經常性損益後的淨利潤5.4億元-6.2億元,同比增長50.98%-73.35%。
公司堅定實施兒童用藥是公司第一核心戰略,堅持打造黃金單品羣驅動品類發展策略。上半年,面對複雜多變的行業市場環境,公司經營管理團隊強化模式領先優勢,動態調整經營策略,調結構、控節奏,抓確定性增長,推動業績穩步提升。
“一小、一老、一婦”為公司特色經營領域。報吿期內,公司兒童用藥及成人用藥品類均呈現增長態勢。兒童用藥領域,第一梯隊的黃金大單品小兒肺熱咳喘口服液/顆粒、小兒柴桂退熱顆粒、小兒氨酚黃那敏顆粒、小葵花露等在高位依然繼續保持良性增長,第二梯隊儲備黃金單品芪斛楂顆粒、小兒泄速停顆粒、小兒麥棗咀嚼片、雙黃連顆粒等在培育期便呈現較高效率,實現較高增長,“小葵花”兒童藥品牌在用户、渠道的品類優勢已經形成,並仍不斷地強化。同時,成人藥品類老慢病領域黃金單品護肝片、胃康靈、美沙拉嗪腸溶片等,婦科用藥領域黃金單品康婦消炎栓、優勢品種益母草顆粒等,上半年均實現預期,有效帶動成人用藥領域各品類整體增長。
2023年半年度業績增長主要系主營業務收入增長驅動。非經常性損益對公司業績預增無重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.